In this scenario, phase 2 clinical trials for RA methods targeting inflammation with steroids and anti-TNFα biologics can be observed in a very short time, often within 4 weeks that typical phase 2 RA trials are performed with these drugs. This evidence concerns the gene TNF and rheumatoid arthritis.